ANI Pharmaceuticals Inc
ANIP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.78B
Close$
$-54.62
172.6% downside
Current Fair Value
172.6% downsideOvervalued by 172.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $1.81 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.5 |
| Beta | 0.46 |
| Outstanding Shares | 20,914,000 |
Return
| Return on Equity | 16.68% |
|---|---|
| Return on Assets | 6.60% |
| Return on Invested Capital | 11.72% |
Valuation & Multiples
| P/E Ratio | 18.31 |
|---|---|
| PEG | 20.79 |
| Price to Sales | 1.71 |
| Price to Book Ratio | 2.89 |
| Enterprise Value to Revenue | 1.96 |
| Enterprise Value to EBIT | 13.04 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$1.28
Average shareholder expectationRevenue Estimate
$207.63 M
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$2.05
Average shareholder expectationRevenue Estimate
$263.79 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0612▼ 18.14% |
|---|---|
| Total Calls | 202,500▲ 42.01% |
| Total Puts | 417,400▲ 30.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.20%▲ 10.76% |
|---|---|
| Total Invested | $1.79B▲ 7.19% |
| Investors Holding | 284▼ 8.00% |
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...